CL2014002975A1 - Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2. - Google Patents
Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.Info
- Publication number
- CL2014002975A1 CL2014002975A1 CL2014002975A CL2014002975A CL2014002975A1 CL 2014002975 A1 CL2014002975 A1 CL 2014002975A1 CL 2014002975 A CL2014002975 A CL 2014002975A CL 2014002975 A CL2014002975 A CL 2014002975A CL 2014002975 A1 CL2014002975 A1 CL 2014002975A1
- Authority
- CL
- Chile
- Prior art keywords
- cells
- surveillance
- diagnosis
- cancer
- ratio
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4915—Blood using flow cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G01N33/57545—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Ecology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20120174539 EP2682750A1 (en) | 2012-07-02 | 2012-07-02 | In vitro method for the diagnosis and surveillance of cancer |
| US201261672941P | 2012-07-18 | 2012-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002975A1 true CL2014002975A1 (es) | 2015-04-24 |
Family
ID=46397089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002975A CL2014002975A1 (es) | 2012-07-02 | 2014-11-03 | Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20150337384A1 (enExample) |
| EP (2) | EP2682750A1 (enExample) |
| JP (1) | JP2015526709A (enExample) |
| KR (1) | KR20150035521A (enExample) |
| CN (1) | CN104364656A (enExample) |
| AU (1) | AU2013286134A1 (enExample) |
| BR (1) | BR112014026661A2 (enExample) |
| CA (1) | CA2872668A1 (enExample) |
| CL (1) | CL2014002975A1 (enExample) |
| EA (1) | EA201500080A1 (enExample) |
| HK (1) | HK1202618A1 (enExample) |
| IL (1) | IL236197A0 (enExample) |
| IN (1) | IN2015DN00678A (enExample) |
| MX (1) | MX2014013079A (enExample) |
| PH (1) | PH12014502436A1 (enExample) |
| SG (1) | SG11201406581UA (enExample) |
| WO (1) | WO2014005909A1 (enExample) |
| ZA (1) | ZA201409298B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| CA2940115C (en) | 2014-02-24 | 2023-03-14 | Ventana Medical Systems, Inc. | Methods, kits, and systems for scoring the immune response to cancer by simultaneous detection of cd3, cd8, cd20 and foxp3 |
| JP2017512493A (ja) * | 2014-03-14 | 2017-05-25 | ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． | 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復 |
| US20160266125A1 (en) * | 2015-03-12 | 2016-09-15 | John Wayne Cancer Institute | Methods of treating and predicting progression of cancer based on t cell subsets |
| US20180193391A1 (en) * | 2015-06-22 | 2018-07-12 | President And Fellows Of Harvard College | Induction of lamina propria regulatory t cells |
| JP6100867B1 (ja) * | 2015-11-06 | 2017-03-22 | 振武 曽 | 免疫状態の分析のための検査方法 |
| CN106932576A (zh) * | 2017-03-22 | 2017-07-07 | 山东大学深圳研究院 | 一种人调节性t细胞的免疫抑制功能的检测方法 |
| JP7255896B2 (ja) * | 2017-05-19 | 2023-04-11 | ロイヤル・メルボルン・インスティテュート・オブ・テクノロジー | シクロホスファミド療法に対する応答者の予測 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN108508196B (zh) * | 2018-04-13 | 2020-10-27 | 何韶衡 | 一种检测人调节性t细胞亚型的试剂盒及检测方法 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| KR102873348B1 (ko) | 2018-07-10 | 2025-10-20 | 노파르티스 아게 | 3-(5-하이드록시-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 ikaros 패밀리 아연 핑거 2(ikzf2)-의존성 질환의 치료에 있어서의 이의 용도 |
| JP7259019B2 (ja) * | 2018-09-20 | 2023-04-17 | ヴェンタナ メディカル システムズ， インク． | フローサイトメトリデータを分析するためのサイズに基づくゲーティング |
-
2012
- 2012-07-02 EP EP20120174539 patent/EP2682750A1/en not_active Withdrawn
-
2013
- 2013-06-27 BR BR112014026661A patent/BR112014026661A2/pt not_active IP Right Cessation
- 2013-06-27 SG SG11201406581UA patent/SG11201406581UA/en unknown
- 2013-06-27 HK HK15102870.4A patent/HK1202618A1/xx unknown
- 2013-06-27 AU AU2013286134A patent/AU2013286134A1/en not_active Abandoned
- 2013-06-27 EP EP13731798.8A patent/EP2867677A1/en not_active Withdrawn
- 2013-06-27 CN CN201380030845.9A patent/CN104364656A/zh active Pending
- 2013-06-27 CA CA2872668A patent/CA2872668A1/en not_active Abandoned
- 2013-06-27 MX MX2014013079A patent/MX2014013079A/es unknown
- 2013-06-27 EA EA201500080A patent/EA201500080A1/ru unknown
- 2013-06-27 JP JP2015519081A patent/JP2015526709A/ja active Pending
- 2013-06-27 WO PCT/EP2013/063448 patent/WO2014005909A1/en not_active Ceased
- 2013-06-27 US US14/410,365 patent/US20150337384A1/en not_active Abandoned
- 2013-06-27 IN IN678DEN2015 patent/IN2015DN00678A/en unknown
- 2013-06-27 KR KR20147030813A patent/KR20150035521A/ko not_active Withdrawn
-
2014
- 2014-10-30 PH PH12014502436A patent/PH12014502436A1/en unknown
- 2014-11-03 CL CL2014002975A patent/CL2014002975A1/es unknown
- 2014-12-11 IL IL236197A patent/IL236197A0/en unknown
- 2014-12-17 ZA ZA2014/09298A patent/ZA201409298B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014502436A1 (en) | 2015-01-12 |
| SG11201406581UA (en) | 2015-01-29 |
| EA201500080A1 (ru) | 2015-06-30 |
| CN104364656A (zh) | 2015-02-18 |
| EP2682750A1 (en) | 2014-01-08 |
| JP2015526709A (ja) | 2015-09-10 |
| IN2015DN00678A (enExample) | 2015-06-26 |
| HK1202618A1 (en) | 2015-10-02 |
| BR112014026661A2 (pt) | 2017-06-27 |
| ZA201409298B (en) | 2015-12-23 |
| US20150337384A1 (en) | 2015-11-26 |
| CA2872668A1 (en) | 2014-01-09 |
| AU2013286134A1 (en) | 2015-01-22 |
| EP2867677A1 (en) | 2015-05-06 |
| WO2014005909A1 (en) | 2014-01-09 |
| MX2014013079A (es) | 2014-12-08 |
| IL236197A0 (en) | 2015-01-29 |
| KR20150035521A (ko) | 2015-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002975A1 (es) | Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2. | |
| IL262359A (en) | Ex vivo bite-activated t cells | |
| BR112015001592A8 (pt) | análise de imagem e medidas de amostras biológicas | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| WO2016040775A8 (en) | Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography | |
| MX374399B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
| BR112015008621A2 (pt) | Métodos e kit de diagnóstico e/ou prognóstico in vitro microconjunto de ácidos nucleicos. | |
| WO2016063068A3 (en) | Method and apparatus for the analysis of compounds | |
| BR112015032544A2 (pt) | bactéria probiótica compreendendo metais, nanopartículas de metal e usos das mesmas | |
| MX2016004865A (es) | Metodo y dispositivo para analizar relacion social. | |
| MX2017005888A (es) | Dispositivos, sistemas y metodos para la deteccion de analitos. | |
| AR107786A1 (es) | Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal | |
| MX2015012341A (es) | Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos. | |
| MX2017006970A (es) | Metodo basado en celulas para determinar la potencia de la defibrotida. | |
| MX2015015015A (es) | Metodo para diagnosticar cancer. | |
| AR099753A1 (es) | Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro | |
| WO2015175526A3 (en) | Methods and compositions for caliciviridae | |
| WO2016069612A3 (en) | Biomarkers for early diagnosis and differentiation of mycobacterial infection | |
| IT201600109735A1 (it) | Biomarcatori e metodi per la diagnosi in vitro di sclerosi multipla. | |
| WO2015107430A3 (en) | Methods and biomarkers for detection and prognosis of cervical cancer | |
| JP2016064626A5 (enExample) | ||
| BR112014032456A2 (pt) | métodos in vitro, composição farmacêutica, kit para realização do método e método para melhorar o efeito de tratamento | |
| IT201600069927A1 (it) | Metodo per la diagnosi in vitro di carcinoma tiroideo. | |
| WO2016096640A3 (en) | Anti-cxcl12 antibody molecules and their uses | |
| GB201105129D0 (en) | Compositions and methods for treating, diagnosing and monitoring disease |